Molecular Weight(MW): 392.49
Ivacaftor (VX-770) is a selective potentiator of CFTR targeting G551D-CFTR and F508del-CFTR with EC50 of 100 nM and 25 nM in fisher rat thyroid cells, respectively.
Cited by 14 Publications
7 Customer Reviews
(A) CFTR Western blot of normal (NL) and CF HBE cultures treated with VX-809 (5 uM) ± VX-770 (5 uM) for 48 hours. “*” indicates the mature, complex glycosylated form of CFTR, band C; “•” indicates the immature band B. (B) Turnover of rescued ΔF508 in BHK-21 cells. ΔF508 was rescued at 27°C in the presence of VX-809 ± VX-770 for 24 hours. After adding cycloheximide (200 ug/ml, 37°C), cells were lysed at the indicated times and analyzed by Western blotting.
Sci Transl Med 2014 6(246), 246ra96. Ivacaftor (VX-770) purchased from Selleck.
Treatment with DF508 CFTR correcting drugs (VX-770 and VX-809, 10 lM) partially redistributed F-actin in the submembrane compartment as also shown by the two small membrane peaks in the quantification graph. Treatment with PP2 (1 lM) alone or in combination with VX-770 and VX-809 completely recovered the actin distribution in DF508-chol similar to Control-chol. Phalloidin fluorescence intensity confirms the presence of membrane sharper peaks that reach intensity values comparable to Control-chol. Abbreviations: A.U, arbitrary units; chol, cholangiocytes.
Hepatology, 2018, 67(3):972-988. Ivacaftor (VX-770) purchased from Selleck.
(A, B) Liquid absorption (Jv) was assessed in expanded alveolar epithelial cells from WT pigs under basal conditions (A) or following treatment with forskolin+IBMX (5+50 μmol/L, B) in the absence or presence of 10 μmol/L ivacaftor. n=10 transwells from 3 pigs.
Crit Care Med, 2017, 45(12):e1240-e1246. Ivacaftor (VX-770) purchased from Selleck.
(A) Representative traces of Ca2+ mobilization induced by 100 μm of OAG after modulation of CFTR activity with 10 μm VX-770. (B) Histograms show normalized AUC corresponding to Ca2+ mobilization induced by 100 μm OAG (n, number of cells recorded/N, number of cell passages).
Ivacaftor (VX-770) purchased from Selleck.
Purity & Quality Control
Choose Selective CFTR Inhibitors
|Description||Ivacaftor (VX-770) is a selective potentiator of CFTR targeting G551D-CFTR and F508del-CFTR with EC50 of 100 nM and 25 nM in fisher rat thyroid cells, respectively.|
|Features||The first potent and orally available CFTR potentiator to enter human clinical trials.|
Ivacaftor (10 μM) significantly increases the forskolin-stimulated Cl- secretion (IT) by ~4-fold with an EC50 of 100 nM in the recombinant Fisher rat thyroid (FRT) cells expressing G551D gating mutation of CFTR, and by ~6-fold with an EC50 of 25 nM in the recombinant cells expressing temperature-corrected F508del processing mutation of CFTR. Consistent with the increases in the forskolin-stimulated IT, Ivacaftor (10 μM) increases the open probability (Po) of G551D-, F508del-, and wild-type CFTR by ~6-fold, ~5-fold and ~2-fold, respectively, indicating that Ivacaftor acts directly on CFTR to increase its gating activity. In primary cultured human CF bronchial epithelia (HBE) carrying the G551D and F508del CFTR mutations, Ivacaftor (10 μM) potently increases the forskolin-stimulated IT by ~10-fold from 5% to a maximum level of 48% of that measured in non-CF HBE, with an EC50 of 236 nM displaying ~70-fold more potency compared with the commonly used CFTR potentiator genistein, which has an EC50 of 16 μM. In HBE with F508del homozygous CFTR, Ivacaftor causes a significant increase in the forskolin-stimulated IT with an EC50 of 22 nM, to a less extent from 4% to 16% of non-CF HBE compared with the effect in G551D/F508del HBE. Due to CFTR potentiation, Ivacaftor inhibits excessive ENaC-mediated Na+ and fluid absorption with an IC50 of 43 nM, and decreases the amiloride response, resulting in an increase in the surface fluid and cilia beat frequency (CBF) in G551D/F508del HBE. 
|In vitro||DMSO||78 mg/mL (198.73 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03439865||Not yet recruiting||Chronic Rhinosinusitis (Diagnosis)||University of Alabama at Birmingham|National Heart Lung and Blood Institute (NHLBI)||July 2019||Early Phase 1|
|NCT03251911||Not yet recruiting||Chronic Bronchitis||University of Alabama at Birmingham||January 1 2019||Phase 4|
|NCT03624101||Not yet recruiting||Cystic Fibrosis||University of Alabama at Birmingham||November 1 2018||Early Phase 1|
|NCT02653027||Withdrawn||Diabetes|Cystic Fibrosis||Massachusetts General Hospital||January 1 2018||Not Applicable|
|NCT03277196||Recruiting||Cystic Fibrosis||Vertex Pharmaceuticals Incorporated||August 16 2017||Phase 3|
|NCT03068312||Active not recruiting||Cystic Fibrosis||Vertex Pharmaceuticals Incorporated||July 18 2017||Phase 3|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.